WO2014140933A8 - Procédé de pronostic et de traitement de métastases cancéreuses - Google Patents

Procédé de pronostic et de traitement de métastases cancéreuses Download PDF

Info

Publication number
WO2014140933A8
WO2014140933A8 PCT/IB2014/001253 IB2014001253W WO2014140933A8 WO 2014140933 A8 WO2014140933 A8 WO 2014140933A8 IB 2014001253 W IB2014001253 W IB 2014001253W WO 2014140933 A8 WO2014140933 A8 WO 2014140933A8
Authority
WO
WIPO (PCT)
Prior art keywords
relates
cancer
metastasis
bone metastasis
gene
Prior art date
Application number
PCT/IB2014/001253
Other languages
English (en)
Other versions
WO2014140933A2 (fr
WO2014140933A3 (fr
Inventor
Roger GOMIS
Evarist Planet
Milica Pavlovic
Anna ARNAL
Maria TARRAGONA
Original Assignee
Fundacio Institut De Recerca Biomedica (Irb Barcelona)
Institucio Catalana De Recerca I Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201480015564.0A priority Critical patent/CN105324491B/zh
Application filed by Fundacio Institut De Recerca Biomedica (Irb Barcelona), Institucio Catalana De Recerca I Estudis Avancats filed Critical Fundacio Institut De Recerca Biomedica (Irb Barcelona)
Priority to MX2015011362A priority patent/MX2015011362A/es
Priority to AU2014229505A priority patent/AU2014229505B2/en
Priority to KR1020157026432A priority patent/KR20150122731A/ko
Priority to EP14747411.8A priority patent/EP2971113B1/fr
Priority to JP2015562411A priority patent/JP6577873B2/ja
Priority to BR112015023783A priority patent/BR112015023783A2/pt
Priority to US14/776,412 priority patent/US20160032400A1/en
Priority to CA2906394A priority patent/CA2906394A1/fr
Publication of WO2014140933A2 publication Critical patent/WO2014140933A2/fr
Publication of WO2014140933A3 publication Critical patent/WO2014140933A3/fr
Publication of WO2014140933A8 publication Critical patent/WO2014140933A8/fr
Priority to US17/241,571 priority patent/US20210317534A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La présente invention concerne un procédé de pronostic de métastases osseuses dans un cancer, qui comprend l'utilisation d'une sonde pour déterminer si un gène d'intérêt est amplifié dans un échantillon de tumeur primaire. L'invention porte en outre sur un procédé permettant de déterminer la tendance à développer des métastases osseuses par rapport aux métastases dans d'autres organes, qui comprend l'utilisation d'une sonde pour déterminer le niveau d'expression d'un gène d'intérêt, ou l'amplification ou la translocation d'un gène d'intérêt. L'invention a également trait à un procédé permettant de prévoir de manière précoce l'apparition de métastases osseuses chez un sujet atteint d'un cancer. Par ailleurs, l'invention porte sur un inhibiteur du c-MAF en tant qu'agent thérapeutique à utiliser dans le traitement de métastases cancéreuses. L'invention concerne en outre des kits permettant de prévoir l'apparition de métastases osseuses et le résultat clinique d'un sujet souffrant de métastases osseuses. Enfin, l'invention a trait à un procédé de typage d'un sujet atteint de cancer et de classification dudit sujet atteint de cancer dans une cohorte.
PCT/IB2014/001253 2013-03-15 2014-03-14 Procédé de pronostic et de traitement de métastases cancéreuses WO2014140933A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2015562411A JP6577873B2 (ja) 2013-03-15 2014-03-14 がんの転移の予後診断および処置のための方法
MX2015011362A MX2015011362A (es) 2013-03-15 2014-03-14 Metodo para el pronostico y tratamiento de metastasis de cancer.
AU2014229505A AU2014229505B2 (en) 2013-03-15 2014-03-14 Method for the prognosis and treatment of cancer metastasis
KR1020157026432A KR20150122731A (ko) 2013-03-15 2014-03-14 암 전이의 예후 및 치료 방법
EP14747411.8A EP2971113B1 (fr) 2013-03-15 2014-03-14 Procédé de pronostic et de traitement de métastases cancéreuses
CN201480015564.0A CN105324491B (zh) 2013-03-15 2014-03-14 用于癌症转移的诊断和治疗的方法
BR112015023783A BR112015023783A2 (pt) 2013-03-15 2014-03-14 método para diagnóstico e tratamento de metastase no câncer
US14/776,412 US20160032400A1 (en) 2013-03-15 2014-03-14 Method for the prognosis and treatment of cancer metastasis
CA2906394A CA2906394A1 (fr) 2013-03-15 2014-03-14 Procede de pronostic et de traitement de metastases cancereuses
US17/241,571 US20210317534A1 (en) 2013-03-15 2021-04-27 Method for the prognosis and treatment of cancer metastasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361801718P 2013-03-15 2013-03-15
US61/801,718 2013-03-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/776,412 A-371-Of-International US20160032400A1 (en) 2013-03-15 2014-03-14 Method for the prognosis and treatment of cancer metastasis
US17/241,571 Continuation US20210317534A1 (en) 2013-03-15 2021-04-27 Method for the prognosis and treatment of cancer metastasis

Publications (3)

Publication Number Publication Date
WO2014140933A2 WO2014140933A2 (fr) 2014-09-18
WO2014140933A3 WO2014140933A3 (fr) 2014-12-31
WO2014140933A8 true WO2014140933A8 (fr) 2020-10-01

Family

ID=51265712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/001253 WO2014140933A2 (fr) 2013-03-15 2014-03-14 Procédé de pronostic et de traitement de métastases cancéreuses

Country Status (10)

Country Link
US (2) US20160032400A1 (fr)
EP (1) EP2971113B1 (fr)
JP (1) JP6577873B2 (fr)
KR (1) KR20150122731A (fr)
CN (1) CN105324491B (fr)
AU (1) AU2014229505B2 (fr)
BR (1) BR112015023783A2 (fr)
CA (1) CA2906394A1 (fr)
MX (2) MX2015011362A (fr)
WO (1) WO2014140933A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058018A2 (fr) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Prédiction de l'évolution d'un cancer
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP2427575B1 (fr) 2009-05-07 2018-01-24 Veracyte, Inc. Méthodes pour le diagnostic d'affections thyroïdiennes
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
KR101944555B1 (ko) 2010-10-06 2019-02-01 펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나) 유방암 전이의 진단, 예후 및 치료 방법
CA2858581A1 (fr) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Diagnostics du cancer a l'aide de transcriptions non codantes
EP2650682A1 (fr) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Esters asymétriques d'acides gras utiles en tant que lubrifiants
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
EP2906718B1 (fr) 2012-10-12 2019-05-15 Inbiomotion S.L. Méthode pour le diagnostic, le pronostic et le traitement d'une métastase du cancer de la prostate en utilisant c-maf
WO2014186036A1 (fr) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd)
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN107206043A (zh) 2014-11-05 2017-09-26 维拉赛特股份有限公司 使用机器学习和高维转录数据在经支气管活检上诊断特发性肺纤维化的系统和方法
EP3229909B1 (fr) 2014-12-11 2020-10-14 Inbiomotion S.L. Eléments de liaison pour c-maf humain
EP3417877A4 (fr) * 2016-02-18 2019-10-02 Kyoto University Complexe capable d'inhiber la fonction génétique dans un exosome, et suppresseur de la prolifération et/ou de la métastase cancéreuses
CA3020329A1 (fr) * 2016-04-08 2017-10-12 The Cleveland Clinic Foundation Nanoparticules pour l'administration de medicament destinees a traiter une maladie osseuse
US20190218302A1 (en) * 2016-05-19 2019-07-18 Probiocon Gmbh Anti-cancer combination treatment
MX2018014279A (es) * 2016-05-25 2019-07-08 Inbiomotion Sl Tratamiento terapeutico de cancer de mama con base en estado de c-maf.
KR20190028726A (ko) * 2016-07-12 2019-03-19 더 유니버시티 오브 노스캐롤라이나 앳 채플 힐 암 진단 및 모델링에 사용하기 위한 바이오매트릭스 스캐폴드
CN110506127B (zh) 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (fr) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Signatures genetiques pour predire une metastase du cancer de la prostate et identifier la virulence d'une tumeur
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
CA3082728A1 (fr) 2017-11-22 2019-05-31 Inbiomotion S.L. Traitement therapeutique du cancer du sein sur la base de c-maf
CN108084254A (zh) * 2017-11-30 2018-05-29 天津市湖滨盘古基因科学发展有限公司 一种人的抗癌基因WWOXδ6-8突变蛋白及其应用
WO2021185959A1 (fr) * 2020-03-19 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Agonistes du récepteur alpha des oestrogènes pour le traitement et le pronostic de métastases osseuses
WO2024168138A2 (fr) * 2023-02-08 2024-08-15 Iogenetics, Llc Vaccins à base de néo-antigènes expedités
CN115919464B (zh) * 2023-03-02 2023-06-23 四川爱麓智能科技有限公司 肿瘤定位方法、系统、装置及肿瘤发展预测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU580145B2 (en) 1985-02-13 1989-01-05 Scios Nova Inc. Human metallothionein-ii promoter in mammalian expression system
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
IL126418A0 (en) 1996-04-05 1999-05-09 Salk Inst For Biological Studi Hormone-mediated methods for modulating expression of exogenous genes and pharmaceutical compositions for modulating the same
JP2002509431A (ja) 1996-12-23 2002-03-26 イミュネックス・コーポレーション ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
CA2368148A1 (fr) 1999-03-15 2000-09-21 Axys Pharmaceuticals, Inc. Nouveaux composes et compositions comme inhibiteurs de protease
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
EP1248612B1 (fr) 2000-01-06 2008-02-27 Merck Frosst Canada Ltd. Nouveaux composes et compositions utilises comme inhibiteurs de protease
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
MXPA04000134A (es) 2001-06-26 2005-06-06 Abgenix Inc Anticuerpos para ligandos de osteoprotegerina.
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
AU2003903540A0 (en) 2003-07-09 2003-07-24 Atdec Pty Ltd Flat panel display wall mounting system
US20050060771A1 (en) 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (fr) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation de la fonction du systeme immunitaire par la modulation des polypeptides arginine-methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (fr) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition de l'expression genique et ses usages therapeutiques
US8242081B2 (en) 2005-12-06 2012-08-14 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2007081879A2 (fr) * 2006-01-05 2007-07-19 Novartis Ag Méthodes pour prévenir et traiter des métastases de cancer et des pertes osseuses associées à des métastases de cancer
WO2008098351A1 (fr) 2007-02-14 2008-08-21 University Health Network Traitement de maladies prolifératives médiées par la d-cycline et de malignités hématologiques
KR20120125601A (ko) 2007-05-24 2012-11-16 아블린쓰 엔.브이. Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
CA2729521A1 (fr) * 2008-07-02 2010-01-07 Assistance Publique Hopitaux De Paris Procede pour predire le resultat clinique de patients atteints de carcinome bronchique a grandes cellules
KR101944555B1 (ko) * 2010-10-06 2019-02-01 펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나) 유방암 전이의 진단, 예후 및 치료 방법
WO2012064967A2 (fr) * 2010-11-10 2012-05-18 Cedars-Sinai Medical Center Le récepteur activateur du ligand nf-kb, issu de cellules cancéreuses, entraîne des métastases des os et des tissus mous
EP2650682A1 (fr) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Esters asymétriques d'acides gras utiles en tant que lubrifiants
BR112014030750A2 (pt) * 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar

Also Published As

Publication number Publication date
BR112015023783A2 (pt) 2017-10-24
JP6577873B2 (ja) 2019-09-18
MX2015011362A (es) 2015-12-16
US20210317534A1 (en) 2021-10-14
CN105324491B (zh) 2021-10-26
WO2014140933A2 (fr) 2014-09-18
CA2906394A1 (fr) 2014-09-18
KR20150122731A (ko) 2015-11-02
AU2014229505B2 (en) 2020-02-27
AU2014229505A1 (en) 2015-09-03
US20160032400A1 (en) 2016-02-04
CN105324491A (zh) 2016-02-10
EP2971113A2 (fr) 2016-01-20
MX2020001156A (es) 2020-03-12
EP2971113B1 (fr) 2020-08-12
JP2016516403A (ja) 2016-06-09
WO2014140933A3 (fr) 2014-12-31

Similar Documents

Publication Publication Date Title
WO2014140933A8 (fr) Procédé de pronostic et de traitement de métastases cancéreuses
WO2015052583A3 (fr) Méthode de pronostic et de traitement d'une métastase cancéreuse
WO2013153458A3 (fr) Méthode de pronostic et de traitement de métastases cancéreuses
WO2014184679A3 (fr) Procédé de pronostic et de traitement de la métastase d'un carcinome des cellules rénales
WO2013182912A3 (fr) Méthode pour le diagnostic, le pronostic et le traitement d'une métastase du cancer du poumon
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
EP4282405A3 (fr) Détection de biomarqueurs du cancer à l'aide de nanoparticules
WO2014057357A3 (fr) Méthode pour le diagnostic, le pronostic et le traitement d'une métastase du cancer de la prostate
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
Weller et al. The role of tumour FoxP3 as prognostic marker in different subtypes of head and neck cancer
WO2013033629A3 (fr) Méthodes et compositions pour le traitement et le diagnostic du cancer colorectal
NZ599194A (en) Methods to predict clinical outcome of cancer
JP2014144959A5 (fr)
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
WO2006091776A3 (fr) Biomarqueurs destines a predire la progression d'un cancer de la prostate
WO2012045905A3 (fr) Méthode de diagnostic, pronostic et traitement de la métastase du cancer du sein
JP2016500110A5 (fr)
WO2015176066A3 (fr) Protéine associée à lpa et expression d'arn
MY179845A (en) Specific biomarker set for non-invasive diagnosis of liver cancer
WO2017217807A3 (fr) Biomarqueur comprenant la nckap1 en tant qu'ingrédient efficace pour le diagnostic du cancer colorectal ou pour la prédiction de métastases et le pronostic du cancer colorectal
WO2019074615A3 (fr) Procédés in vitro de découverte de composés thérapeutiques pour la peau à l'aide de biomarqueurs de vieillissement de la peau
Zhou et al. Increased expression of long non-coding RNA SBDSP1 correlates with poor survival in colorectal cancer
WO2016161153A3 (fr) Procédés de diagnostic et de pronostic du cancer colorectal
WO2010093907A3 (fr) Dosage pour la détection de récurrence du cancer du sein utilisant le nouveau suppresseur de tumeur dear1
WO2013010140A3 (fr) Procédés de diagnostic du cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480015564.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/011362

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014229505

Country of ref document: AU

Date of ref document: 20140314

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014747411

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015562411

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2906394

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14776412

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20157026432

Country of ref document: KR

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14747411

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015023783

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015023783

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150915